Back to mobile site

Stifel Reiterates Buy Rating on Oruka Therapeutics (ORKA)

March 7, 2025 7:41 AM EST Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $49.00 price target on Oruka Therapeutics (NASDAQ: ORKA)The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login